000143730 001__ 143730
000143730 005__ 20240229112606.0
000143730 0247_ $$2doi$$a10.3390/cancers11040584
000143730 0247_ $$2pmid$$apmid:31027243
000143730 037__ $$aDKFZ-2019-01300
000143730 041__ $$aeng
000143730 082__ $$a610
000143730 1001_ $$aRong, Chao$$b0
000143730 245__ $$aDifferential Activation of ERK Signaling in HPV-Related Oropharyngeal Squamous Cell Carcinoma.
000143730 260__ $$aBasel$$bMDPI$$c2019
000143730 3367_ $$2DRIVER$$aarticle
000143730 3367_ $$2DataCite$$aOutput Types/Journal article
000143730 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1637569427_30857
000143730 3367_ $$2BibTeX$$aARTICLE
000143730 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143730 3367_ $$00$$2EndNote$$aJournal Article
000143730 520__ $$aHuman papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) forms a distinct tumor entity with better survival clinical outcome. Numerous underlying molecular mechanisms have been postulated for differences in treatment response, but the impact of MEK/ERK signaling, a main driver of carcinogenesis in various cancers including OPSCC and key player mediating therapy resistance remains elusive. In a retrospective experimental cohort study, primary tumor samples from OPSCC patients (n = 124) were available on tissue microarrays (TMAs) and expression levels of phosphorylated ERK1/2 (pERK1/2) were detected by immunohistochemical staining. Correlations of pERK1/2 expression patterns with clinicopathological features and clinical outcome were evaluated by statistical analysis. A low pERK1/2 expression was strongly associated with HPV-related OPSCC, while primary tumors with high pERK1/2 staining showed a distinctly worse survival outcome and were associated with higher cellular differentiation. Co-activation of both ERK1/2 and AKT was a common event and was associated with unfavorable prognosis in our cohort. However, the combinatorial analysis of pAKT (Ser473) and pERK1/2 did not strengthen the predictive power of pERK1/2, suggesting that pERK1/2 plays a more significant function in OPSCC. In summary, our data provide a compelling experimental and statistical evidence that low levels of tumor cell intrinsic ERK1/2 activation contribute at least in part to the favorable outcome of HPV-related OPSCC. On the other hand, presented findings indicate that non-HPV-related OPSCC with elevated ERK phosphorylation are at high risk for treatment failure and might benefit from targeted therapy of MEK/ERK signaling.
000143730 536__ $$0G:(DE-HGF)POF3-319H$$a319H - Addenda (POF3-319H)$$cPOF3-319H$$fPOF III$$x0
000143730 588__ $$aDataset connected to CrossRef, PubMed,
000143730 7001_ $$aMuller, Marie$$b1
000143730 7001_ $$aFlechtenmacher, Christa$$b2
000143730 7001_ $$0P:(DE-He78)d84ca2cd7f160904c387ee699735076c$$aHolzinger, Dana$$b3$$udkfz
000143730 7001_ $$aDyckhoff, Gerhard$$b4
000143730 7001_ $$aBulut, Olcay Cem$$b5
000143730 7001_ $$aHorn, Dominik$$b6
000143730 7001_ $$aPlinkert, Peter$$b7
000143730 7001_ $$0P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f$$aHess, Jochen$$b8$$udkfz
000143730 7001_ $$aAffolter, Annette$$b9
000143730 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers11040584$$gVol. 11, no. 4, p. 584 -$$n4$$p584$$tCancers$$v11$$x2072-6694$$y2019
000143730 909CO $$ooai:inrepo02.dkfz.de:143730$$pVDB
000143730 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d84ca2cd7f160904c387ee699735076c$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000143730 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000143730 9131_ $$0G:(DE-HGF)POF3-319H$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vAddenda$$x0
000143730 9141_ $$y2019
000143730 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2017
000143730 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143730 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143730 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143730 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000143730 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000143730 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000143730 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review
000143730 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000143730 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000143730 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000143730 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143730 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143730 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143730 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000143730 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2017
000143730 9201_ $$0I:(DE-He78)F022-20160331$$kF022$$lInfektionen und Krebs-Epidemiologie$$x0
000143730 9201_ $$0I:(DE-He78)F020-20160331$$kF020$$lInfektionen und Krebs-Epidemiologie$$x1
000143730 9201_ $$0I:(DE-He78)A102-20160331$$kA102$$lMolekulare Grundlagen von HNO-Tumoren$$x2
000143730 980__ $$ajournal
000143730 980__ $$aVDB
000143730 980__ $$aI:(DE-He78)F022-20160331
000143730 980__ $$aI:(DE-He78)F020-20160331
000143730 980__ $$aI:(DE-He78)A102-20160331
000143730 980__ $$aUNRESTRICTED